News | September 30, 2011

First Robotic Radiosurgery Prostate Cancer Registry Enrolls More than 500 Men

September 30, 2011 — The CyberKnife Coalition announced that more than 500 men have been enrolled in the first national patient registry designed to track prostate cancer patients treated with stereotactic body radiation therapy (SBRT). All of the patients were treated with the CyberKnife Robotic Radiosurgery System.

The multi-institutional Registry for Prostate Cancer Radiosurgery (RPCR) tracks clinical and functional outcomes of men with localized prostate cancer treated at academic and community based centers throughout the United States.

Launched in July 2010, the RPCR is an independent, Institutional Review Board (IRB)-approved observational trial registered with clinicaltrials.gov. It is designed to collect information that will be useful in determining the role of radiosurgical treatment for patients with early-stage prostate cancer.

In addition to tracking clinical data the registry also collects patient selection and quality of life information, which will be reported to the Centers for Medicare & Medicaid Services (CMS) and local Medicare contractors.

By participating in the registry, CyberKnife centers will be better equipped to help patients make the best decision for their individual circumstances, a view shared by the Agency for Healthcare Quality and Research. The agency published a patient guide earlier this month entitled 'Knowing your Treatment Options', an overview of prostate cancer treatment options, that for the first time included SBRT as a treatment option for men with localized prostate cancer.

For more information: www.ckcoalition.org

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Overlay Init